SAB Biotherapeutics (SABS) Receives Grant for SAB-142 Assessment

On July 7, SAB Biotherapeutics Inc. (NASDAQ: SABS) received a research grant from Breakthrough T1D to support the PRISE-hATG clinical assessment of SAB-142 in Stage 3 type 1 diabetes patients. This assessment focuses on individuals diagnosed between 100 days and 2 years and aims to evaluate SAB-142's effectiveness in preserving C-peptide levels and regulating immune responses. Eliana Merle from Barclays has rated the stock as Overweight with a target price of $13, suggesting over 240% upside potential. The Phase 2b data for this immunotherapy is expected in the second half of 2027, which could be significant for investors.